[Ip-health] Update on first Compulsory License application in India for cancer drug – Sorafenib
shailly.17 at gmail.com
Mon Jan 16 23:00:04 PST 2012
Update on first Compulsory License application in India for cancer drug –
In the first hearing held on 13 Jan '12 on Natco's CL application for
Sorafenib (generic version of Bayer's Nexaver), the Controller General of
Patents had asked Bayer, German drug maker to submit cost data, including
research and development expenditure on Nexavar to justify the
substantially high price. Click
read more about the case hearing reported by Livemint.
The second hearing will take place next month. Bayer had argued in the
hearing that it is not possible for it to sell the drug at a lower cost as
the investment made on the drug can't be recovered with the price lower
than the one currently being offered. Bayer sell Nexaver at the cost of Rs.
2.8 lacks per month.
See a graphical representation of the stark difference between the price
being offered for this drug by Bayer (originator company) and the two
generics (Cipla & Natco) in India.
Medecins Sans Frontieres
Campaign for Access to Essential Medicines
C 236 Defence Colony, New Delhi, India
Tel: +91 11 46573731, +91 11 46573730
More information about the Ip-health